4D Molecular Therapeutics annual free cash flow
2019
2020
2021
2022
2023
2024
2025
4D Molecular Therapeutics Free Cash Flow (FCF) History (FDMT)
4D Molecular Therapeutics reported −$109.6M in free cash flow for fiscal 2025, an increase of $28.8M from the previous fiscal year, with a free cash flow margin of −128.65%.
View full 4D Molecular Therapeutics company overview4D Molecular Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$109.6M | $28.8M | — | −128.65% |
| 2024 | 2024-12-31 | −$138.4M | −$59.8M | — | −373975.68% |
| 2023 | 2023-12-31 | −$78.6M | $19.7M | — | −379.11% |
| 2022 | 2022-12-31 | −$98.2M | −$20.0M | — | −3139.05% |
| 2021 | 2021-12-31 | −$78.2M | −$26.3M | — | −433.77% |
| 2020 | 2020-12-31 | −$51.9M | −$12.0M | — | −388.45% |
| 2019 | 2019-12-31 | −$39.9M | — | — | −573.48% |
4D Molecular Therapeutics quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $28.5M | $75.3M | — | +33.47% |
| Q3 2025 | 2025-09-30 | −$46.6M | −$15.4M | — | −51765.56% |
| Q2 2025 | 2025-06-30 | −$43.4M | −$12.9M | — | −289620.00% |
| Q1 2025 | 2025-03-31 | −$48.4M | −$18.6M | — | −345635.71% |
| Q4 2024 | 2024-12-31 | −$46.8M | −$21.6M | — | −4681200.00% |
| Q3 2024 | 2024-09-30 | −$31.2M | −$29.6M | — | −1038966.67% |
| Q2 2024 | 2024-06-30 | −$30.6M | −$7.7M | — | −611840.00% |
| Q1 2024 | 2024-03-31 | −$29.8M | −$880,000 | — | −106421.43% |
| Q4 2023 | 2023-12-31 | −$25.2M | −$1.9M | — | — |
| Q3 2023 | 2023-09-30 | −$1.6M | $21.4M | — | −7.80% |
| Q2 2023 | 2023-06-30 | −$22.9M | −$900,000 | — | −9569.04% |
| Q1 2023 | 2023-03-31 | −$28.9M | $1.0M | — | −9704.03% |
| Q4 2022 | 2022-12-31 | −$23.3M | $3.6M | — | −1867.55% |
| Q3 2022 | 2022-09-30 | −$23.0M | −$4.6M | — | −4596.20% |
| Q2 2022 | 2022-06-30 | −$22.0M | −$5.0M | — | −13561.73% |
| Q1 2022 | 2022-03-31 | −$30.0M | −$13.9M | — | −2458.00% |
| Q4 2021 | 2021-12-31 | −$26.9M | −$8.9M | — | −29273.91% |
| Q3 2021 | 2021-09-30 | −$18.4M | −$4.6M | — | −1343.78% |
| Q2 2021 | 2021-06-30 | −$16.9M | −$10.7M | — | −116.20% |
| Q1 2021 | 2021-03-31 | −$16.0M | −$1.4M | — | −800.70% |
| Q4 2020 | 2020-12-31 | −$18.0M | — | — | — |
| Q3 2020 | 2020-09-30 | −$13.7M | — | — | −184.88% |
| Q2 2020 | 2020-06-30 | −$6.3M | — | — | −179.28% |
| Q1 2020 | 2020-03-31 | −$14.6M | — | — | −427.76% |
4D Molecular Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$51.9M to −$109.6M, a net decrease of $57.7M. 4D Molecular Therapeutics's latest reported quarter, Q4 2025, generated $28.5M in free cash flow, an increase of $75.3M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review 4D Molecular Therapeutics filings at SEC.gov ↗